LDL-C
A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C
... The LDL-C to HDL-C ratio (LHR) was calculated and divided into the first, second, and third ...in LDL-C while most patients ...increased LDL-C ...that LDL-C ...
8
Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II
... particularly LDL-C, while Ɛ2 is LDL-C lowering allele when compared to Ɛ3 ...on LDL-C have been shown by many researchers [17 – ...with LDL- C levels, their effect ...
9
Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia
... Circulating LDL-c guarantees a constant supply of cholesterol for tissues and cells; cholesterol is required for membrane synthesis, modulation of membrane fluid- ity and regulation of cell signaling ...
10
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
... At baseline, the percentages of patients who were at LDL-C levels of ,1.8 and ,2.6 mmol/L (70 and 100 mg/dL) were significantly higher in the titrator than add-on groups for all statins (Figure 3). In ...
9
Evaluation of different formulas for LDL-C calculation
... measure LDL directly. The principle of D-LDL-C determination is as follows: At pH ...enabling LDL-C mea- surement by a conventional enzymatic reaction with cholesterol oxidase, ...
9
Moving beyond LDL-C: incorporating lipoprotein particle numbers and geometric parameters to improve clinical outcomes
... (high LDL-P) potentially indentified by the NMR technique is not meaningful, or do we take note that when discordant, in many cited studies, LDL-P was a better predictor of CVD events, than were ...
10
Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials
... in LDL-C and HDL-C ...baricinitib-induced LDL-C change gradually increased as the extended dur- ation of treatment (week 12 to 52), however, the HDL-C in- crease was similar at ...
11
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
... In 2003, Maxwell and co-workers first identified PCSK9 as a novel target gene of SREBP and demon- strated that hepatic PCSK9 mRNA levels were signifi- cantly increased in SREBP-1a and SREBP-2 transgenic mice [41]. In ...
10
A Study Of Hdl-C & Ldl-C In Myocardial Infraction: Atheroscleosis.
... Triacylglyceride, LDL-c is higher level & lower level of ...cholesterol, LDL-c, VLDL & Chylomicron were significantly increased , HDL-c are decreased in both age groups of CHD ...
6
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
... goal LDL-C of 100 mg/dL following 8 weeks of ...of LDL to HDL and non lipid-lowering effects such as flow-mediated endothelium- dependent dilation (FMD), flow-mediated endothelium inde- pendent ...
11
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
... the LDL-C lowering effect was 21% when rosuvastatin and ezetimibe were used concomitantly, and 6% when the rosuvastatin dose was doubled [14], the num- ber of subjects required was calculated to be 32 ...
9
Prevalence and characteristics of patients with low levels of low-density lipoprotein cholesterol in northern Denmark: a descriptive study
... of LDL-C measurements and calendar time for each region, registration in the Central Denmark region did not appear as complete as that in the North Denmark region until 2005, when taking their relative ...
12
Implications of Recent Clinical Trials for the National Cholesterol JACC.pdf
... further LDL-lowering therapy for this ...between LDL-C level and CHD risk implies that further reduction in risk could be achieved by still more LDL lowering ...the LDL-C goal of ...
13
Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease
... or LDL-C levels in humans and animal models [30, 31], suggesting a po- tential link of MMP-9 rs3918242 polymorphism to serum ...and LDL-C levels before simvastatin treat- ...robust ...
6
Accuracy of low-density lipoprotein cholesterol estimation at very low levels
... low LDL-C levels outside of those with gen- etically low LDL-C [15, ...at LDL-C < 40 mg/dL ...on-treatment LDL-C levels were < 25 mg/dL, and medication was ...
11
Lipid Profile Abnormalities in People Living with HIV and AIDS
... The occurrence of dyslipidaemia is well recorded in HIV-infected persons, even prior to treatment with HAART. High density lipoprotein (HDL) Cholesterol (HDL-C) and Low Density Lipoprotein (LDL) - ...
79
Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital
... the LDL-C goal. According to our results, patients whose LDL-C goal should have been lower, and who required treatment with statins of higher potency, received statins of low-to-moderate ...
5
Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study
... profile, C-reactive protein and aGLP- 1 ...method. LDL-cholesterol (LDL-C) was esti- mated by Friedewald ...respectively. C-reactive protein (CRP) was de- termined by high sensitivity ...
7
<p>High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus</p>
... the LDL-C and lipid ratio parameters (TC/HDL-C, LDL-C/HDL-C, non-HDL-C) have a signi fi cant association as risk factors for the occurrence of poor glycemic control ...
9
Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
... on LDL-C reduction, as reported in numerous clinical scenarios, the inhibition of PCSK9 appears to be a promising approach to reduce the risk for cardiovascular ...evolocumab-induced LDL-C ...
7